Patel Keval, Gupta Nandini, Prajapati Bela J, Prajapati Arpit, Sharma Shweta, Rathava Dhara
Department of OtoRhinoLaryngology Civil Hospital, Ahmedabad, Gujarat India.
Indian J Otolaryngol Head Neck Surg. 2023 Apr;75(Suppl 1):804-808. doi: 10.1007/s12070-022-03366-w. Epub 2022 Dec 29.
Allergic Rhinitis is one of the most common allergic disease and characterized by sneezing, rhinorrhea, nasal congestion and nasopharyngeal itching. The initial management includes pharmacological treatment and the patients who are refractory to pharmacological treatment are then reffered for immunotherapy. SLIT has been widely used for treatment of allergic rhinitis and has proven its clinical efficacy. The objective of the present study was to assess the clinical effects, safety and tolerability of sublingual immunotherapy (SLIT) among the patients suffering from allergic rhinitis. The study was conducted from Aug 2018 to April 2021 and 40 patients with convincing history, positive skin prick test to one or more allergen extracts were recruited. SLIT was conducted with antigens (mix), namely dust mites, tree pollens, grass pollens and weed pollens in patients of allergic rhinitis for 1 year. There was significant improvement in quality of life and symptoms severity(Nasal and Non-Nasal) from base line to end of 1 year. SLIT lowers the total IgE, absolute eosinophilic count and medication requirement. Sublingual Immunotherapy for specific allergens decreases clinical symptoms in patients with allergic rhinitis and sensitivity to multiple allergen.
过敏性鼻炎是最常见的过敏性疾病之一,其特征为打喷嚏、流涕、鼻塞和鼻咽部瘙痒。初始治疗包括药物治疗,对药物治疗无效的患者则转诊接受免疫治疗。舌下免疫治疗(SLIT)已广泛用于治疗过敏性鼻炎,并已证明其临床疗效。本研究的目的是评估舌下免疫治疗(SLIT)在过敏性鼻炎患者中的临床效果、安全性和耐受性。该研究于2018年8月至2021年4月进行,招募了40例有确切病史、对一种或多种变应原提取物皮肤点刺试验呈阳性的患者。对过敏性鼻炎患者使用抗原(混合制剂)进行舌下免疫治疗1年,抗原包括尘螨、树花粉、草花粉和杂草花粉。从基线到1年末,生活质量和症状严重程度(鼻部和非鼻部)有显著改善。舌下免疫治疗可降低总IgE、绝对嗜酸性粒细胞计数和药物需求。针对特定变应原的舌下免疫治疗可减轻过敏性鼻炎患者的临床症状并降低对多种变应原的敏感性。